Mechanisms of gene amplification and evidence of coamplification in drug-resistant human osteosarcoma cell lines

Genes Chromosomes and Cancer

Volumn 48, Issue 4, 2009, Pages 289-309

  Hattinger, Claudia M ^a   Stoico, Giuseppina ^a   Michelacci, Francesca ^a   Pasello, Michela ^a   Scionti, Isabella ^a   Remondini, Daniel ^b   Castellani, Gastone C ^b   Fanelli, Marilù ^a   Scotlandi, Katia ^a   Picci, Piero ^a   Serra, Massimo ^a,c  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c Laboratorio di Ricerca Onco Logica   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFOLATE REDUCTASE; DOXORUBICIN; METHOTREXATE; MIXED LINEAGE LEUKEMIA PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; GLYCOPROTEIN P; MLL PROTEIN, HUMAN;

ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE IDENTIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; ONCOGENE MYC; OSTEOSARCOMA CELL; PRIORITY JOURNAL; STAINING; UPREGULATION; DNA MICROARRAY; DRUG RESISTANCE; GENE DOSAGE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; OSTEOSARCOMA; POLYMERASE CHAIN REACTION; REPRODUCIBILITY; TUMOR CELL LINE; TUMOR GENE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COMPARATIVE GENOMIC HYBRIDIZATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; GENES, NEOPLASM; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; METHOTREXATE; MYELOID-LYMPHOID LEUKEMIA PROTEIN; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOSARCOMA; P-GLYCOPROTEIN; POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; TETRAHYDROFOLATE DEHYDROGENASE;

EID: 62149098010     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20640     Document Type: Article

References (37)

1. Albertson DG. 2006. Gene amplification in cancer. Trends Genet 22:447-455.
2. Atiye J, Wolf M, Kaur S, Monni O, Böhling T, Kivioja A, Tas E, Serra M, Tarkkanen M, Knuutila S. 2005. Gene amplifications in osteosarcoma-CGH microarray analysis. Genes Chromosomes Cancer 42:158-163.
3. Benner SE, Wahl GM, Von Hoff DD. 1991. Double minute chromosomes and homogeneously staining regions in tumors taken directly from patients versus in human tumor cell lines. Anti- cancer Drugs 2:11-25.
4. Buys TPH, Chari R, Lee EHL, Zhang M, MacAulay C, Lam S, Lam WL, Ling V. 2007. Genetic changes in the evolution of multidrug resistance for cultured human ovarian cancer cells. Genes Chromosomes Cancer 46:1069-1079.
5. Chou AJ, Gorlick R. 2006. Chemotherapy resistance in osteosar- coma: Current challenges and future directions. Expert Rev Anticancer Ther 6:1075-1085.
6. Coquelle A, Pipiras E, Toledo F, Buttin G, Debatisse M. 1997. Expression of fragile sites triggers intrachromosomal mammalian gene amplification and sets boundaries to early amplicons. Cell 89:215-225.
7. Dean M, Rzhetsky A, Allikmets R. 2001. The human ATP-bind- ing cassette (ABC) transporter superfamily. Genome Res 11:1156-1166.
8. dos Santos Aguiar S, de Jesus Girotto Zambaldi L, dos Santos AM, Pinto W, Jr., Brandalise SR. 2007. Comparative genomic hybridization analysis of abnormalities in chromosome 21 in childhood osteosarcoma. Cancer Genet Cytogenet 175:35-40.
9. Flahaut M, Mühlethaler-Mottet A, Martinet D, Fattet S, Balmas Bourloud K, Auderst K, Meier R, Besuchet Schmutz N, Delattre O, Joseph J-M, Gross N. 2006. Molecular cytogenetic characterization of doxurubicin-resistant neuroblastoma cell lines: Evidence that acquired multidrug resistance results from a unique large amplification of the 7q21 region. Genes Chromosomes Cancer 45:495-508.
10. Gamberi G, Benassi MS, Bohling, Ragazzini P, Molendini L, Sol- lazzo MR, Pompetti F, Merli M, Magagnoli G, Balladelli A, Picci P. 1998. C-myc and c-fos in human osteosarcoma: Prognostic value of mRNA and protein expression. Oncology 55:556-563.
11. Gebhart E. 2005. Double minutes, cytogenetic equivalents of gene amplification, in human neoplasia. Clin Transl Oncol 7:477-485.
12. Hattinger CM, Reverter-Branchat G, Remondini D, Castellani GC, Benini S, Pasello M, Manara MC, Scotlandi K, Picci P, Serra M. 2003. Genomic imbalances associated with methotrex- ate resistance in human osteosarcoma cell lines detected by comparative genomic hybridization-based techniques. Eur J Cell Biol 82:483-493.
13. Kakazu N, Taniwaki M, Horiike S, Nishida K, Tatekawa T, Nagai M, Takahashi T, Akaogi T, Inazawa J, Ohki M, Abe T. 1999. Combined spectral karyotyping and DAPI banding analysis of chromosome abnormalities in myelodysplastic syndrome. Genes Chromosomes Cancer 26:336-345.
14. Knuutila S, Autio K, Aalto Y. 2000. Online access to CGH data of DNA sequence copy number changes. Am J Pathol 157:689.
15. Kuttler F, Mai S. 2007. Formation of non-random extrachromoso- mal elements during development, differentiation and oncogen- esis. Semin Cancer Biol 17:56-64.
16. Ladanyi M, Park CK, Lewis R, Jhanwar SC, Healey JH, Huvos AG. 1993. Sporadic amplification of the MYC gene in human osteosarcomas. Diagn Mol Pathol 2:163-167.
17. Lim G, Karaskova J, Beheshti B, Vukovic B, Bayani, Selvarajah S, Watson SK, Lam WL, Zielenska M, Squire JA. 2005. An integrated mBAND and submegabase resolution tiling set (SMRT) CGH array analysis of focal amplification, microdeletions, and ladder structures consistent with breakage-fusion-bridge cycle events in osteosarcoma. Genes Chromosomes Cancer 42:392403.
18. Ma C, Martin S, Trask B, Hamlin JL. 1993. Sister chromatid fusion initiates amplification of the dihydrofolate reductase gene in chinese hamster cells. Genes Dev 7:605-620.
19. Manara MC, Perdichizzi S, Serra M, Pierini R, Benini S, Hat- tinger CM, Astolfi A, Bagnati R, d'Incalci M, Picci P, Scotlandi K. 2005. The molecular mechansims responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing's sarcoma cell line, TC-71. Int J Oncol 27:1605-1616.
20. Myllykangas S, Knuutila S. 2006. Manifestation, mechanisms and mysteries of gene amplification. Cancer Lett 232:79-89.
21. Pakos EE, Ioannidis JP. 2003. The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A meta-analysis. Cancer 98:581-589.
22. Papenhausen PR, Griffin S, Tepperberg J. 2005. Oncogene amplification in transforming myelodysplasia. Exp Mol Pathol 79:168-175.
23. Pompetti F, Rizzo P, Simon RM, Freidlin B, Mew DJ, Pass HI, Picci P, Levine AS, Carbone M. 1996. Oncogene alterations in primary, recurrent, and metastatic human bone tumors. J Cell Biochem 63:37-50.
24. Poppe B, Vandesompele J, Schoch C, Lindvall C, Mrozek K, Bloomfield CD, Beverloo HB, Michaux L, Dastugue N, Herens C, Yigit N, de Paepe A, Hagemeijer A, Speleman F. 2004. Expression analyses indentify MLL as a prominent target of 11q23 amplification and support an etiologic role for MLL gain of function in myeloid malignancies. Blood 103:229-235.
25. Sandberg AA, Bridge JA. 2003. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: Osteo- sarcoma and related tumors. Cancer Genet Cytogenet 145:130.
26. Scionti I, Michelacci F, Pasello M, Hattinger CM, Alberghini M, Manara MC, Bacci G, Ferrari S, Scotlandi K, Picci P, Serra M. 2008. Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high- grade osteosarcoma. Ann Oncol 19:1500-1508.
27. Scotlandi K, Serra M, Manara MC, Lollini P-L, Maurici D, del Bufalo D, Baldini N. 1994. Pre-treatment of human osteosarcoma cells with N-methylformamide enhances P-glycoprotein expression and resistance to doxorubicin. Int J Cancer 58:95-101.
28. Scotlandi K, Serra M, Nicoletti G, Vaccari M, Manara MC, Nini G, Landuzzi L, Colacci A, Bacci G, Bertoni F, Picci P, Campa- nacci M, Baldini N. 1996. Multidrug resistance and malignancy in human osteosarcoma. Cancer Res 56:2434-2439.
29. Serra M, Scotlandi K, Manara MC, Maurici D, Lollini P-L, de Giovanni C, Toffoli G, Baldini N. 1993. Establishment and characterization of multidrug-resistant human osteosarcoma cell lines. Anticancer Res 13:323-330.
30. Serra M, Scotlandi K, Reverter-Branchat G, Ferrari S, Manara MC, Benini S, Incaprera M, Bertoni F, Mercuri M, Briccoli A, Bacci G, Picci P. 2003. Value of P-glycoprotein and clinicopath- ologic factors as the basis for new treatment strategies in high- grade osteosarcoma of the extremities. J Clin Oncol 21:536-542.
31. Serra M, Reverter-Branchat G, Maurici D, Benini S, Shen JN, Chano T, Hattinger CM, Manara MC, Pasello M, Scotlandi K, Picci P. 2004. Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells. Ann Oncol 15:151-160.
32. Serra M, Pasello M, Manara MC, Scotlandi K, Ferrari S, Bertoni F, Mercuri M, Alvegard TA, Picci P, Bacci G, Smeland S. 2006. May P-glycoprotein status be used to stratify high-grade osteo- sarcoma patients? Results from the Italian/Scandinavian sarcoma group 1 treatment protocol. Int J Oncol 29:1459-1468.
33. Snijders AM, Hermsen MA, Baughman J, Buffart TE, Huey B, Gajduskova P, Roydasgupta R, Tokuyasu T, Meijer GA, Fri- dlyand J, Albertson DG. 2008. Acquired genomic aberrations associated with methotrexate resistance vary with background genomic instability. Genes Chromosomes Cancer 47:71-83.
34. Stock C, Kager L, Fink F-M, Gadner H, Ambros PF. 2000. Chromosomal regions involved in the pathogenesis of osteosarcoma. Genes Chromosomes Cancer 28:329-336.
35. Trask BJ, Hamlin JL. 1989. Early dihydrofolate reductase gene amplification events in CHO cells usually occur on the same chromosome arm as the original locus. Genes Dev 3:1913-1925.
36. Wang YC, Juric D, Francisco B, Yu RX, Duran GE, Chen GK, Chen X, Sikic BI. 2006. Regional activation of chromosomal arm 7q with and without gene amplification in taxane-selected human ovarian cancer cell lines. Genes Chromosomes Cancer 45:365-374.
37. Yasui K, Mihara S, Zhao C, Okamoto H, Saito-Ohara F, Tomida A, Funato T, Yokomizo A, Naito S, Imoto I, Tsuruo T, Inazawa J. 2004. Alteration in copy numbers of genes as a mechansim for acquired drug resistance. Cancer Res 64:1403-1410.